Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): Innovative drug BIOS0629-109 tablets approved to conduct clinical trials.
Baicheng Pharmaceutical (301096.SZ) announced that its innovative drug BIOS0629-109, developed in collaboration with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd., has received the Clinical Trial Approval Notification from the National Medical Products Administration (NMPA). BIOS0629-109 is a novel XPO1 inhibitor intended for the treatment of late-stage malignant tumors, classified as a Class 1 chemical drug for registration.
Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that the innovative drug BIOS0629-109 tablets, developed in collaboration with Zhejiang Zhongshen Innovate Pharmaceutical Technology Co., Ltd., has obtained a clinical trial approval notification from the National Medical Products Administration (NMPA). BIOS0629-109 is a new type of XPO1 inhibitor intended for the treatment of advanced malignant tumors, classified as a category 1 chemical drug.
Related Articles
CHICMAX (02145) issued 148,500 restricted stock units according to the incentive plan.
As of the end of June, Hangzhou Tigermed Consulting (03347) had repurchased a total of 20.9635 million A-shares.
.png)
CHICMAX (02145) granted a total of 182,300 restricted stock units.
CHICMAX (02145) issued 148,500 restricted stock units according to the incentive plan.
As of the end of June, Hangzhou Tigermed Consulting (03347) had repurchased a total of 20.9635 million A-shares.
CHICMAX (02145) granted a total of 182,300 restricted stock units.
RECOMMEND
